Understanding how a specific protein complex contributes to lung scarring in a serious lung disease.
Profibrotic Mechanisms of the TRPV4-PI3K-gamma Protein Complex
This study is looking at how certain proteins in the lungs work together and how they might help us find new ways to treat idiopathic pulmonary fibrosis (IPF), a serious lung disease that causes scarring, so that patients can have better treatment options in the future.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10828870 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind idiopathic pulmonary fibrosis (IPF), a severe lung condition characterized by scarring. The focus is on a protein complex involving TRPV4 and PI3Kγ, which plays a crucial role in the differentiation of myofibroblasts, the cells responsible for fibrosis. By studying how these proteins interact and respond to changes in lung tissue stiffness, the research aims to uncover new therapeutic targets to prevent or treat this debilitating disease. Patients may benefit from insights that could lead to innovative treatments for IPF.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis or those at risk of developing this condition.
Not a fit: Patients with other forms of lung disease unrelated to fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively treat or even reverse lung scarring in patients with idiopathic pulmonary fibrosis.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in fibrosis, indicating potential for success in this novel approach.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Lerner Com-Cwru — Cleveland, United States (Active)
Researchers
- Principal investigator: Olman, Mitchell Alan — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Olman, Mitchell Alan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.